All Studies Meta Analysis

Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports

Enyeji et al., Viral Immunology, doi:10.1089/vim.2024.0034

Aug 2024

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Tixagevimab/cilgavimab

38th treatment shown to reduce risk in May 2022, now with p = 0.000029 from 17 studies, recognized in 31 countries. Efficacy is variant dependent.

Lower risk for mortality, hospitalization, and cases.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 112 treatments. c19early.org

Review of the successful treatment of COVID-19 using existing medications including HCQ, AZ, ivermectin, famotidine, monoclonal antibodies, and others. Authors note that the typical treatment of severe viral infections with multiple therapeutic agents has generally not been done in COVID-19 clinical trials, that different mechanisms of action from multiple treatments can minimize the emergence of drug-resistant SARS-CoV-2 strains, and that early treatment disrupts viral replication, avoids progression to cytokine storm, and is critical to avoid long-term complications.

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.

Reviews covering tixagevimab/cilgavimab for COVID-19 include5-8.

Important missing comments or errors? Let us know.

Review covers ivermectin, HCQ, famotidine, bebtelovimab, tixagevimab/cilgavimab, and sotrovimab.

1. Planas et al., Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies, bioRxiv, doi:10.1101/2022.11.17.516888.biorxiv.org, doi.org.

2. Haars et al., Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, Microorganisms, doi:10.3390/microorganisms11102417.mdpi.com, doi.org.

3. Uraki et al., Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate, iScience, doi:10.1016/j.isci.2023.108147.sciencedirect.com, doi.org.

4. Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines, doi:10.3390/vaccines11101533.mdpi.com, doi.org.

5. Focosi, D., Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities, Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268.springer.com, doi.org.

6. Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.liebertpub.com, doi.org.

7. Focosi (B) et al., Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment, Drug Resistance Updates, doi:10.1016/j.drup.2023.100991.sciencedirect.com, doi.org.

8. Keam, S., Tixagevimab + Cilgavimab: First Approval, Drugs, doi:10.1007/s40265-022-01731-1.springer.com, doi.org.

Enyeji et al., 5 Aug 2024, peer-reviewed, 3 authors.

This Paper Tixagev../c..All

{ 'indexed': {'date-parts': [[2024, 8, 6]], 'date-time': '2024-08-06T00:25:30Z', 'timestamp': 1722903930363}, 'reference-count': 14, 'publisher': 'Mary Ann Liebert Inc', 'license': [ { 'start': { 'date-parts': [[2024, 8, 5]], 'date-time': '2024-08-05T00:00:00Z', 'timestamp': 1722816000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.1089/vim.2024.0034', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 3]], 'date-time': '2024-08-03T11:03:52Z', 'timestamp': 1722683032000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports', 'prefix': '10.1089', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2653-8605', 'authenticated-orcid': False, 'given': 'Abraham M.', 'family': 'Enyeji', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Community Medicine, Mercer University School of ' 'Medicine, Columbus, Georgia, 31901, USA.'}]}, { 'given': 'Amit', 'family': 'Arora', 'sequence': 'additional', 'affiliation': [ { 'name': 'Georgetown University, Data Science and Analytics Washington, DC ' '20057, USA.'}]}, { 'given': 'Harpal S.', 'family': 'Mangat', 'sequence': 'additional', 'affiliation': [ { 'name': 'Germantown Medical Health Center, Germantown, Maryland, 20876 ' 'USA.'}]}], 'member': '278', 'published-online': {'date-parts': [[2024, 8, 5]]}, 'reference': [ {'key': 'B1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/978-3-030-88863-3_14'}, {'key': 'B2', 'doi-asserted-by': 'publisher', 'DOI': '10.13016/i1wo-er4h'}, {'key': 'B4', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciac663'}, {'key': 'B5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.rce.2020.05.006'}, {'key': 'B6', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamaoto.2020.1922'}, {'key': 'B7', 'doi-asserted-by': 'publisher', 'DOI': '10.7554/eLife.59177'}, {'key': 'B8', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms22115438'}, { 'issue': '2', 'key': 'B9', 'first-page': '1088', 'volume': '17', 'author': 'Mangat HS', 'year': '2023', 'journal-title': 'Health Sci J'}, { 'key': 'B10', 'doi-asserted-by': 'publisher', 'DOI': '10.29121/granthaalayah.v8.i7.2020.678'}, {'key': 'B11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jinf.2020.07.005'}, {'key': 'B12', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/head.14006'}, {'key': 'B13', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.envres.2020.109754'}, {'key': 'B14', 'doi-asserted-by': 'publisher', 'DOI': '10.34172/jrip.2020.19'}, {'key': 'B15', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/SCIADV.ABD4049'}], 'container-title': 'Viral Immunology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.liebertpub.com/doi/full-xml/10.1089/vim.2024.0034', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.liebertpub.com/doi/pdf/10.1089/vim.2024.0034', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 8, 5]], 'date-time': '2024-08-05T14:00:56Z', 'timestamp': 1722866456000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.liebertpub.com/doi/10.1089/vim.2024.0034'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 8, 5]]}, 'references-count': 14, 'alternative-id': ['10.1089/vim.2024.0034'], 'URL': 'http://dx.doi.org/10.1089/vim.2024.0034', 'relation': {}, 'ISSN': ['0882-8245', '1557-8976'], 'subject': [], 'container-title-short': 'Viral Immunology', 'published': {'date-parts': [[2024, 8, 5]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0